🇺🇸 FDA

Intelligence · Clinical Pipeline

Anaxis Pharma Pipeline

All ClinicalTrials.gov programs at Anaxis Pharma — phase, modality, and trial IDs.

Programs
204

Quick answer

Anaxis Pharma has 204 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Evaluation of bioequivalence of two products containing 400 mg ibuprofen and 100 mg caffeine: Ibuprofen / Caffeine 400 mg / 100 mg coated granules (Test) vs. Thomapyrin TENSION DUO, 400mg / 100mg Filmtabletten (Reference). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  2. Evaluation of bioequivalence of two products containing 50 mg dimenhydrinate: Dimenhydrinate 50 mg (Test) vs. Vomex A 50 mg Lösung zum Einnehmen im Beutel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  3. Evaluation of bioequivalence of two products containing 600 mg ibuprofen: Ibuprofen Sopharma 600 mg film-coated tablets (Test) vs. Brufen 600 mg film-coated tablets (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  4. Evaluation of the bioavailability of two transdermal gel preparations containing 0.1% w/w estradiol under fasting conditions: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA® 0.1%, gel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy postmenopausal women

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  5. Evaluation of vamorolone CYP3A4 induction on midazolam (a sensitive CYP3A4 substrate) pharmacokinetics

    Lacuna Pharma Pty Ltd

    Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy

    phase 1 other active

    1 trial

  6. First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients

    Lacuna Pharma Pty Ltd

    Olmsted syndrome

    phase 1 other active

    1 trial

  7. First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 1 other active

    1 trial

  8. First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis

    Lacuna Pharma Pty Ltd

    Atopic Dermatits

    phase 1 other active

    1 trial

  9. First-in-human Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of the Adjuvanted Universal Influenza Vaccine “fH1/DSP-0546LP” in Healthy Adults

    Lacuna Pharma Pty Ltd

    Influenza

    phase 1 other active

    1 trial

  10. INZ-701, INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency

    phase 1 small molecule active

    1 trial

  11. Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma

    phase 1 other active

    1 trial

  12. Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

    Lacuna Pharma Pty Ltd

    Geographic Atrophy

    phase 1 other active

    1 trial

  13. JR-441

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type IIIA (MPS IIIA)

    phase 1 small molecule active

    1 trial

  14. METRONIDAZOLE, MOLGRAMOSTIM, Saline Solution Basi 9 mg/ml solution for infusion, FOSFOMYCIN

    Lacuna Pharma Pty Ltd

    peritonitis

    phase 1 small molecule active

    1 trial

  15. Methotrexate PK (in combination with Novobiocin) in RA patients

    Lacuna Pharma Pty Ltd

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  16. Minzasolmin, UCB0599 PRD4385815

    Lacuna Pharma Pty Ltd

    Healthy Participants

    phase 1 small molecule active

    1 trial

  17. NXP800 in subjects with Ovarian Cancer

    Lacuna Pharma Pty Ltd

    Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinoma

    phase 1 other active

    1 trial

  18. OMTX705-006 Phase 1b

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  19. Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence study)

    phase 1 other active

    1 trial

  20. PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial

    Lacuna Pharma Pty Ltd

    Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

    phase 1 other active

    1 trial

  21. PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

    Lacuna Pharma Pty Ltd

    relapsed/refractory hematologic malignancies

    phase 1 other active

    1 trial

  22. Paracetamol 1000mg Tablets, Diphenhydramin-Hevert Injektionslösung, Diphenhydramine Hydrochloride Tablets 25 mg, LYNOZYFIC 200 mg concentrate for solution for infusion, LYNOZYFIC 5 mg concentrate for solution for infusion, Dexamethasone 3.3 mg/ml solution for injection/infusion, REGN17372

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 1 small molecule active

    1 trial

  23. Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants

    Lacuna Pharma Pty Ltd

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    phase 1 other active

    1 trial

  24. Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults.

    Lacuna Pharma Pty Ltd

    Healthy Volunteer

    phase 1 other active

    1 trial

  25. Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults.

    Lacuna Pharma Pty Ltd

    Healthy Volunteers

    phase 1 other active

    1 trial

  26. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  27. Phase I Study of PM54 Administered to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Selected Advanced Solid Tumors

    phase 1 other active

    1 trial

  28. Phase I Study of Plitidepsin Administered Intravenously as a Single Dose in Healthy Volunteers

    Lacuna Pharma Pty Ltd

    Virus diseases

    phase 1 other active

    1 trial

  29. Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy participants.

    Lacuna Pharma Pty Ltd

    Androgenetic alopecia

    phase 1 other active

    1 trial

  30. Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced solid tumors

    phase 1 other active

    1 trial

  31. Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)

    Lacuna Pharma Pty Ltd

    Immune-mediated necrotizing myopathy, Antiphospholipid syndrome, Behçet’s Syndrome, Bullous pemphigoid, Dermatomyositis, Immune Thrombocytopenia

    phase 1 other active

    1 trial

  32. Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 1 other active

    1 trial

  33. Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

    Lacuna Pharma Pty Ltd

    Bullous pemphigoid, Behçet’s Syndrome, Dermatomyositis, Antiphospholipid syndrome, Immune-mediated necrotizing myopathy, Immune Thrombocytopenia

    phase 1 other active

    1 trial

  34. Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients with Parkinson’s Disease

    Lacuna Pharma Pty Ltd

    Parkinson’s Disease

    phase 1 other active

    1 trial

  35. RANDOMISED, CROSSOVER, SIMPLE-BLINDED, BIOEQUIVALENCE CLINICAL TRIAL OF ALMOTRIPTAN 12.5 MG ORODISPERSIBLE TABLETS VERSUS ALMOTRIPTAN 12.5 MG FILM-COATED TABLETS, AFTER A SINGLE ORAL DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS UNDER FASTING

    Lacuna Pharma Pty Ltd

    Antimigraine

    phase 1 other active

    1 trial

  36. Randomised, relative bioavailability clinical trial of amylmetacresol, dichlorobenzyl alcohol, lidocaine and vitamin c lozenges after a single oral dose administration to healthy volunteers under fasting conditions in a crossover design.

    Lacuna Pharma Pty Ltd

    healthy volunteer

    phase 1 other active

    1 trial

  37. Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.

    Lacuna Pharma Pty Ltd

    Comparative bioavailability study under fasting conditions

    phase 1 other active

    1 trial

  38. Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is bioavailability)

    phase 1 other active

    1 trial

  39. Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsalicylic acid, tablet, 2.5 mg/50 mg (given as two tablets) to reference product Xarelto 2.5 mg film-coated tablets (given as two tablets) and Aspirin® N 100 mg tablet in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial

  40. Repomol, Metronidazol ”Baxter” Viaflo, infusionsvæske, opløsning, Saline Solution Basi 9 mg/ml solution for infusion, Fosfomycin "Infectopharm", pulver til infusionsvæske, opløsning 40 mg/ml

    Lacuna Pharma Pty Ltd

    peritonitis

    phase 1 small molecule active

    1 trial

  41. SPECT/CT imaging of FPI-2505 in patients with solid tumours; a phase 0 molecular imaging basket trial (SCOPE-study).

    Lacuna Pharma Pty Ltd

    small cell lung cancer, non-smallcell lung cancer, colorectal cancer, breast cancer, Pancreatic cancer and gastric cancer

    phase 1 other active

    1 trial

  42. Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma

    Lacuna Pharma Pty Ltd

    Glaucoma

    phase 1 other active

    1 trial

  43. Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

  44. Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Allergy

    Lacuna Pharma Pty Ltd

    Severe IgE-mediated food allergy

    phase 1 other active

    1 trial

  45. Single dose oral bioequivalence study of Cladribine 10 mg Tablets and Mavenclad® 10 mg tablets (Cladribine) in healthy adult human subjects under fed conditions

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  46. Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

    Lacuna Pharma Pty Ltd

    Squamous Cell Carcinoma of Head and Neck

    phase 1 other active

    1 trial

  47. Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 1 other active

    1 trial

  48. TGD001 SAD study in healthy volunteers

    Lacuna Pharma Pty Ltd

    A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers

    phase 1 other active

    1 trial

Frequently asked questions

How many pipeline programs does Anaxis Pharma have?

204 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.